Status:

UNKNOWN

Identification of a MOLecuLar Signature in Locally Advanced Cervical Cancer Patients

Lead Sponsor:

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Conditions:

Cervical Cancer

Eligibility:

FEMALE

19+ years

Brief Summary

The importance of radioresistance in cervical cancer treatment failure indicates that certain biomarkers may be useful for cervical cancer treatment individualization. However, to date, no study has a...

Detailed Description

The importance of radioresistance in cervical cancer treatment failure indicates that certain biomarkers may be useful for cervical cancer treatment individualization. Several biomarkers of cervical c...

Eligibility Criteria

Inclusion

  • Age \> 18 years
  • Histologically-confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix
  • FIGO 2018 stage IIB and IIIC1\[38\]
  • Treatment with exclusive chemoradiation including brachytherapy
  • Has not previously received any definitive surgical, radiation, or systemic therapy for cervical cancer
  • Has radiographically evaluable disease, measurable per RECIST 1.1
  • Negative pregnancy test
  • Adequate hematologic, renal, and hepatic functions, with following blood tests:
  • Neutrophils \> 1500/μL Platelets \> 100.000/ μL Hemoglobin \> 9 g/dL Serum creatinine \< 1.8 mg/dL Total bilirubin \< 3 mg/ dL LDH \< 3x normal value GOT \< 3x normal value GPT \< 3x normal value ALP \< 3 x normal value

Exclusion

  • Rare cervical cancer histologies (neuroendocrine, glassy cells, serous, endometrioid etc)
  • Neo-adjuvant treatment
  • Patients included in other clinical trials
  • Patients refusing to sign informed consent
  • Contraindications to radiotherapy
  • Contraindications to pelvic radiotherapy: ulcerative colitis, diverticulitis, chronic pelvic inflammatory disease, previous pelvic radiotherapy

Key Trial Info

Start Date :

August 1 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

August 1 2025

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT06016868

Start Date

August 1 2023

End Date

August 1 2025

Last Update

August 30 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Policlinico Universitario Agostino Gemelli, IRCCS

Rome, Italy